Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-In-Human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy In Subjects With Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT05961839 is registered in ClinicalTrials.gov with Schrödinger, Inc. as lead sponsor.

NCT NCT05961839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05961839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-In-Human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy In Subjects With Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Lead sponsor
Schrödinger, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
September 27, 2023
Completion date
September 9, 2025
Enrollment
66 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, high-risk and very high-risk myelodysplastic syndromes